Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta‐analysis of randomized controlled trials and observational studies

References

• Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.
   PubMedGoogle Scholar
• Laheij, R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.
   PubMed Web of Science ®Google Scholar
• Sanduleanu, S., et al. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–388.
   PubMed Web of Science ®Google Scholar
• Lambert, A.A., et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.
   PubMed Web of Science ®Google Scholar
• Eom, C.S., et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. Cmaj. 2011;183(3):310–319.
   PubMed Web of Science ®Google Scholar
• Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–1177.
   PubMed Web of Science ®Google Scholar
• Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980;68(2):255–258.
   PubMed Web of Science ®Google Scholar
• Filion, K.B., et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–558.
   PubMed Web of Science ®Google Scholar
• Liberati, A., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94.
   PubMed Web of Science ®Google Scholar
• Stroup, D.F., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014;4:MR000034.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005;30(3):261–293.
   Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Kantorova, I., et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51(57):757–761.
   PubMedGoogle Scholar
• American Lung Association Asthma Clinical Research, C, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009;360(15):1487–1499.
   PubMed Web of Science ®Google Scholar
• Scheiman, J.M., et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97(10):797–802.
   PubMed Web of Science ®Google Scholar
• Sugano, K., et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011;46(6):724–735.
   PubMed Web of Science ®Google Scholar
• Sugano, K., et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47(5):540–552.
   PubMed Web of Science ®Google Scholar
• Lima, J.J., et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013;163(3):686–691.
   PubMed Web of Science ®Google Scholar
• Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42(5):607–613.
   PubMed Web of Science ®Google Scholar
• Lin, C.C., et al. Stress ulcer prophylaxis in patients being weaned from the ventilator in a respiratory care center: a randomized control trial. J Formos Med Assoc. 2016;115(1):19–24.
   PubMed Web of Science ®Google Scholar
• Selvanderan, S.P., et al. Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med. 2016;44(10):1842–1850.
   PubMed Web of Science ®Google Scholar
• Alhazzani, W., et al. Withholding pantoprazole for stress ulcer prophylaxis in critically Ill patients: a pilot randomized clinical trial and meta-analysis. Crit Care Med. 2017;45(7):1121–1129.
   PubMed Web of Science ®Google Scholar
• van de Garde, E.M., et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006;27(6):1217–1222.
   PubMed Web of Science ®Google Scholar
• Gulmez, S.E., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950–955.
   PubMedGoogle Scholar
• Hennessy, S., et al. Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures. J Clin Epidemiol. 2007;60(9):911–918.
   PubMed Web of Science ®Google Scholar
• Almirall, J., et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31(6):1274–1284.
   PubMed Web of Science ®Google Scholar
• Beaulieu, M., et al. Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit? J Crit Care. 2008;23(4):513–518.
   PubMed Web of Science ®Google Scholar
• Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–398.
   PubMed Web of Science ®Google Scholar
• Herzig, S.J., et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–2128.
   PubMed Web of Science ®Google Scholar
• Marciniak, C., et al. Examination of selected clinical factors and medication use as risk factors for pneumonia during stroke rehabilitation: a case-control study. Am J Phys Med Rehabil. 2009;88(1):30–38.
   PubMed Web of Science ®Google Scholar
• Myles, P.R., et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2009;18(4):269–275.
   PubMed Web of Science ®Google Scholar
• Rodriguez, L.A., et al. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology. 2009;20(6):800–806.
   PubMed Web of Science ®Google Scholar
• Roughead, E.E., et al. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust. 2009;190(3):114–116.
   PubMed Web of Science ®Google Scholar
• Dublin, S., et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(8):792–802.
   PubMed Web of Science ®Google Scholar
• Eurich, D.T., et al. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123(1):47–53.
   PubMed Web of Science ®Google Scholar
• Gau, J.T., et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr. 2010;10:45.
   PubMed Web of Science ®Google Scholar
• Redelmeier, D.A., et al. Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ. 2010;340:c2608.
   PubMed Web of Science ®Google Scholar
• Meijvis, S.C., et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J. 2011;38(5):1165–1172.
   PubMed Web of Science ®Google Scholar
• Pasina, L., et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205–210.
   PubMed Web of Science ®Google Scholar
• Ernst, P., et al. Pramipexole use and the risk of pneumonia. BMC Neurol. 2012;12:113.
   PubMed Web of Science ®Google Scholar
• Hermos, J.A., et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis. 2012;54(1):33–42.
   PubMed Web of Science ®Google Scholar
• Liu, C.L., et al. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. J Hypertens. 2012;30(11):2223–2229.
   PubMed Web of Science ®Google Scholar
• Mullerova, H., et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124–1133.
   PubMed Web of Science ®Google Scholar
• Nielsen, A.G., et al. The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care. 2012;16(4):R122.
   PubMed Web of Science ®Google Scholar
• Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med. 2013;28(2):223–230.
   PubMed Web of Science ®Google Scholar
• Juthani-Mehta, M., et al. Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the health, aging, and body composition study. J Am Geriatr Soc. 2013;61(7):1111–1118.
   PubMed Web of Science ®Google Scholar
• Long, M.D., et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240–248.
   PubMed Web of Science ®Google Scholar
• Ramsay, E.N., et al. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol. 2013;13:82.
   PubMed Web of Science ®Google Scholar
• Buendgens, L., et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696 e11–5.
   PubMed Web of Science ®Google Scholar
• de Groot, M.C., et al. Sources of heterogeneity in case-control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia. Eur J Epidemiol. 2014;29(10):767–775.
   PubMed Web of Science ®Google Scholar
• Herzig, S.J., et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–718.
   PubMed Web of Science ®Google Scholar
• Ho, S.W., et al. Population-based cohort study on the risk of pneumonia in patients with non-traumatic intracranial haemorrhage who use proton pump inhibitors. BMJ Open. 2014;4(11):e006710.
   PubMed Web of Science ®Google Scholar
• Im, J.P., et al. Proton pump inhibitor use before percutaneous endoscopic gastrostomy is associated with adverse outcomes. Gut Liver. 2014;8(3):248–253.
   PubMed Web of Science ®Google Scholar
• Kroupa, R., et al. Is there a real risk of the long term medical treatment of gastroesophageal reflux disease? United European Gastroenterol J. 2014;2(1):A264.
   Google Scholar
• Chen, C.H., et al. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease. J Microbiol Immunol Infect. 2015;48(4):390–396.
   PubMedGoogle Scholar
• Ho, S.W., et al. Risk of stroke-associated pneumonia with acid-suppressive drugs: a population-based cohort study. Medicine (Baltimore). 2015;94(29):e1227.
   PubMed Web of Science ®Google Scholar
• Lee, S.W., et al. Proton pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. J Clin Med Res. 2015;7(11):880–883.
   PubMedGoogle Scholar
• Merli, M., et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–369.
   PubMed Web of Science ®Google Scholar
• Ozkan, M.C., et al. Use of proton pump inhibitors in hematopoietic stem cell transplantation does not increase the frequency of febrile neutropenia. Eur Rev Med Pharmacol Sci. 2015;19(21):4105–4110.
   PubMed Web of Science ®Google Scholar
• Terg, R., et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–1060.
   PubMed Web of Science ®Google Scholar
• Bonvicini, D., et al. Type of stress-ulcer prophylaxis and incidence of ventilator-associated pneumonia. Intensive Care Med Exp. 2016;4.
   Google Scholar
• Chatterjee, S., et al. Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case-control study. J Am Geriatr Soc. 2016;64(2):394–400.
   PubMed Web of Science ®Google Scholar
• Courson, A.Y., et al. Routine prophylaxis with proton pump inhibitors and post-transplant complications in kidney transplant recipients undergoing early corticosteroid withdrawal. Clin Transplant. 2016;30(6):694–702.
   PubMed Web of Science ®Google Scholar
• Kawanishi, K., et al. Risk factors for aspiration pneumonia after endoscopic hemostasis. Dig Dis Sci. 2016;61(3):835–840.
   PubMed Web of Science ®Google Scholar
• McCaleb, R.V., et al. Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center. Ann Pharmacother. 2016;50(7):541–547.
   PubMed Web of Science ®Google Scholar
• Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813.
   PubMedGoogle Scholar
• Sasabuchi, Y., et al. Risks and benefits of stress ulcer prophylaxis for patients with severe sepsis. Crit Care Med. 2016;44(7):e464–9.
   PubMed Web of Science ®Google Scholar
• Six, S., et al. Hyperoxemia as a risk factor for ventilator-associated pneumonia. Crit Care. 2016;20(1):195.
   PubMedGoogle Scholar
• Vukadinović, D., et al. Factors associated with early treatment failure in adult hospitalized patients with community-acquired pneumonia. Vojnosanit Pregl. 2017;74(9):803–813.
   Web of Science ®Google Scholar
• Arai, N., et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. PLoS One. 2017;12(1):e0169300.
   PubMed Web of Science ®Google Scholar
• Bang UC, Bendtsen F. The use of proton pump inhibitors is not associated with an increased risk of infections in a cohort of patients with alcoholic cirrhosis from danish nationwide registers. Hepatology. 2017;66:286A.
   PubMed Web of Science ®Google Scholar
• Ho, S.W., et al. Association of proton pump inhibitors usage with risk of pneumonia in dementia patients. J Am Geriatr Soc. 2017;65(7):1441–1447.
   PubMed Web of Science ®Google Scholar
• Hsu, W.T., et al. Risk of pneumonia in patients with gastroesophageal reflux disease: a population-based cohort study. PLoS One. 2017;12(8):e0183808.
   PubMed Web of Science ®Google Scholar
• Rane, P., et al. Risk of pneumonia associated with proton pump inhibitor use among community dwelling adults with gastroesophageal reflux disease. Value Health. 2017;20(5):A179–A180.
   Web of Science ®Google Scholar
• Zirk-Sadowski, J., et al. Risks of longer term proton pump inhibitor exposure in 228,752 older adults. Eur Geriatric Med. 2017;8:S29–S30.
   Google Scholar
• Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13(4):251–256.
   PubMed Web of Science ®Google Scholar
• Torres, A., et al. Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Eur Respir J. 1996;9(8):1729–1735.
   PubMed Web of Science ®Google Scholar
• Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23(1):3–10.
   PubMed Web of Science ®Google Scholar
• Harder, H., et al. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Scand J Gastroenterol. 1999;34(6):551–561.
   PubMed Web of Science ®Google Scholar
• Tani N. [Application of proton pump inhibitor to special conditions; Zollinger-Ellison syndrome]. Nihon Rinsho. 1992;50(1):154–159.
   PubMedGoogle Scholar
• Schneider-Lindner, V., et al. Antibacterial drugs and the risk of community-associated methicillin-resistant Staphylococcus aureus in children. Arch Pediatr Adolesc Med. 2011;165(12):1107–1114.
   PubMedGoogle Scholar
• Wang, J., et al. Alcohol consumption is not protective for systemic lupus erythematosus. Ann Rheum Dis. 2009;68(3):345–348.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28.
   PubMed Web of Science ®Google Scholar
• Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf. 2007;16(3):250–258.
   PubMed Web of Science ®Google Scholar
• Ali AK. The link between proton pump inhibitors and ischemic heart disease could be explained by protopathic bias: a pharmacovigilance analysis. Value Health. 2015;18(7):A373–4.
   PubMed Web of Science ®Google Scholar
• Arfe A, Corrao G. The lag-time approach improved drug-outcome association estimates in presence of protopathic bias. J Clin Epidemiol. 2016;78:101–107.
   PubMed Web of Science ®Google Scholar
• Jacobson, B.C., et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1):51–58.
   PubMed Web of Science ®Google Scholar
• Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med. 2009;4(3):115–123.
   PubMed Web of Science ®Google Scholar
• Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407–410.
   PubMed Web of Science ®Google Scholar
• Calabrese, C., et al. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. Aliment Pharmacol Ther. 2008;28(2):250–255.
   PubMed Web of Science ®Google Scholar
• Hellstrom PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol. 2004;94(3):106–111.
   PubMed Web of Science ®Google Scholar
• Meyer, C., et al. Is publication bias present in gastroenterological research? An analysis of abstracts presented at an annual congress. PeerJ. 2018;6:e4995.
   PubMed Web of Science ®Google Scholar
• Golder, S., et al. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016;13(9):e1002127.
   PubMed Web of Science ®Google Scholar
• Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012;9(4):e1001201.
   PubMed Web of Science ®Google Scholar
• Wieseler, B., et al. Access to regulatory data from the european medicines agency: the times they are a-changing. Syst Rev. 2012;1:50.
   PubMedGoogle Scholar
• Alves C, Macedo AF, Marques FB. Sources of information used by regulatory agencies on the generation of drug safety alerts. Eur J Clin Pharmacol. 2013;69(12):2083–2094.
   PubMed Web of Science ®Google Scholar
• Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83(2):227–246.
   PubMed Web of Science ®Google Scholar
• Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open. 2018;8(1):e019759.
   PubMed Web of Science ®Google Scholar
• Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48(8):851–859.
   PubMedGoogle Scholar